
Following two federal appeals court rulings last year that rejectedFTC actions that had prevented brand-name companies from payingtheir rivals to drop patent challenges, an FTC analysis has foundat least seven agreements made in fiscal 2006 and three in 2005between brand-name drug companies and generic companies. Speakingto the In-House Counsel's Forum on Pharmaceutical Antitrust, FTCcommissioner Jon Leibowitz said that if the appeals court decisionsremain in force, rival drugmakers will have "carte blanche to avoidcompetition and share resulting profits.